Navigation Links
Penn receives $12 million NIH grant to research personalized approach to smoking cessation
Date:9/7/2010

PHILADELPHIA A variety of smoking cessation treatments are currently available for the more than 18 million adult Americans try to quit smoking each year, but success rates vary widely. Despite the importance of quitting smoking, more personalized approaches to smoking cessation treatment are needed to help smokers pick the right method that will work best for them. A major new personalized medicine clinical trial, led by addiction researchers at the University of Pennsylvania, will study how a smokers' genetic make-up influences their quitting success.

A team of researchers led by Caryn Lerman, PhD, professor of Psychiatry at the University of Pennsylvania School of Medicine and Annenberg Public Policy Center, has received a $12 million five-year grant to study the pharmacogenetics of nicotine addiction treatment.

"In an extension of our previous work in the Pharmacogenetics of Nicotine Addiction Treatment (PNAT) research program, we will conduct the first large prospective pharmacogenetic clinical trial of different smoking cessation medications," said Dr. Lerman, who also serves as scientific director of Penn's Abramson Cancer Center. "Smoking is the greatest preventable cause of morbidity and mortality. It is imperative to find better ways to optimize the delivery of specific treatments to increase the success rates for smokers who wish to quit."

Earlier research by the PNAT research program identified a genetically-informed biomarker that reflects individual differences in the rate of nicotine metabolism how quickly nicotine breaks down in the body. This biomarker, referred to as the nicotine metabolite ratio (NMR), reflects genetic variation in the CYP2A6 gene, as well as environmental influences on nicotine metabolism.

Work by Dr. Lerman, Robert Schnoll, PhD, associate professor of Psychiatry at Penn, and PNAT collaborators has shown that the NMR can be used to predict the success of different smoking treatments for individual smokers. The new clinical trial will provide the next definitive step in their efforts to translate the use of this biomarker to clinical practice.

In this study, 1350 adult smokers will have their NMR assessed to determine whether they metabolize nicotine slowly or quickly. They will then be sorted into two groups slow metabolizers and normal metabolizers and randomized to treatment with a placebo, a nicotine patch, or Pfizer's Chantix (varenicline). Each participant will also provide genetic material (DNA) which will be used to identify additional gene variants that may also contribute to nicotine addiction treatment response. The prospective, double-blind placebo-controlled trial will be completed within the next four years.

The cost-effectiveness of the personalized medicine approach will be analyzed by Daniel Polsky, PhD, and Henry Glick, PhD, both from Penn's Leonard Davis Institute of Health Economics, and Daniel Heitjan, PhD, professor of Biostatistics and Statistics at Penn. Demonstrating that by matching smokers to treatment based on the NMR can increase quit rates and be achieved at a reasonable financial cost will support efforts to translate these pharmacogenetic approaches into clinical practice.

The trial is co-led by Dr. Rachel Tyndale at the University of Toronto and includes the University of California, San Francisco, MD Anderson Cancer Center, SRI International, University of Southern California, and the State University of New York at Buffalo. The grant is supported by the National Institute on Drug Abuse, the National Cancer Institute, the National Institute of General Medical Sciences, and the National Human Genome Research Institute as part of the Pharmacogenetics Research Network (PGRN) Initiative.


'/>"/>

Contact: Kim Guenther
kim.guenther@uphs.upenn.edu
215-662-6183
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Health IT program at the University of Texas at Austin receives $2.7 million in federal funding
2. University of Minnesota math institute receives $20.5 million NSF grant
3. College Of Medicine receives $54 million grant for asthma research
4. Louisiana Tech kinesiology professor receives national editorial excellence award
5. UofL receives $3.15 million grant from Helmsley Charitable Trust
6. St. Michaels receives prestigious grants to study trauma
7. Doctor at Cincinnati Childrens receives prestigious NIH MERIT Award
8. Research consortium at CHLA receives $410,000 to study leukemia and lymphoma
9. Keck School of Medicine of USC receives $24 million gift from Sumner M. Redstone
10. UC San Diego receives major clinical and translational science award
11. Lu receives grant from Research to Prevent Blindness organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: